Security key
29842P105
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX)
CUSIP: 29842P105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Shares, no par value
- Shares outstanding
- 52,146,078
- Total 13F shares
- 1,970,076
- Share change
- -197,517
- Total reported value
- $10,889,810
- Price per share
- $5.76
- Number of holders
- 14
- Value change
- -$1,049,985
- Number of buys
- 9
- Number of sells
- 5
Report period
Q2 2025
Institutions
14
Top holders
10
EPRX full security history
Newer quarter: Q3 2025
Previous quarter: Q1 2025
EUPRAXIA PHARMACEUTICALS INC. SEC filings
EUPRAXIA PHARMACEUTICALS INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29842P105
Recent filing periods:
Top shareholders of EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SCOTIA CAPITAL INC. |
13F
|
Company |
3%
|
1,552,679
|
$5,071,821 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.66%
|
342,828
|
$1,125,000 | — | 31 Mar 2025 | |
| TD Waterhouse Canada Inc. |
13F
|
Company |
0.2%
|
104,986
|
$343,259 | — | 31 Mar 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.1%
|
52,250
|
$170,679 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
51,199
|
$167,933 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
34,500
|
$113,160 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.02%
|
12,054
|
$39,417 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.02%
|
11,133
|
$36,517 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
2,700
|
$8,856 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
2,500
|
$8,200 | — | 31 Mar 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
764
|
$2,494 | — | 31 Mar 2025 |
Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) as of Q2 2025
As of 30 Jun 2025,
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,970,076 shares.
The largest 10 holders included
SCOTIA CAPITAL INC., Royal Bank of Canada, GOLDMAN SACHS GROUP INC, UBS Group AG, BANK OF MONTREAL /CAN/, INGALLS & SNYDER LLC, JPMORGAN CHASE & CO, CITADEL ADVISORS LLC, CIBC WORLD MARKET INC., and BANK OF AMERICA CORP /DE/.
This page lists
14
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
11
Q2 2025 holders
14
Holder diff
3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.